Major medical device manufacturing company Stryker has announced the total acquisition of Inari Medical, an American-based medical device company specialising in the treatment of venous thromboembolism. The acquisition, which began in January 2025, was finalised in mid-February for $4.9 billion. Acquiring Inari’s portfolio of venous thrombectomy devices provides Stryker with an entry point into the high-growth peripheral vascular market.
Inari Medical’s portfolio of devices includes the FlowTriever and ClotTriever systems, used to treat pulmonary embolism and deep vein thrombosis respectively. Both systems utilise a minimally invasive procedure to find and remove clots from the body. These devices compete with those from other major cardiovascular device manufacturers Boston Scientific, Terumo and Penumbra. With rising rates of peripheral artery diseases worldwide, including deep vein thrombosis and pulmonary embolism, this acquisition is likely to strengthen Stryker’s position in the overall cardiovascular device market.
According to the GlobalData Medical Intelligence Center, the worldwide thrombectomy device market was worth $2.96 billion in 2024, growing at a compound annual growth rate (CAGR) of 5.48%. In the US alone, the thrombectomy device market is valued at $1.18 billion, growing at a CAGR of 3.38%. Boston Scientific, Teleflex and Inari Medical are the largest manufacturers in this market, and with Stryker's backing, Inari Medical may see greater success.
With the acquisition of Inari Medical finalised, Stryker is poised to break into the lucrative peripheral vascular device market. Inari’s expertise in thrombectomy devices, combined with Stryker’s existing distribution and logistics network, could result in an improvement in both volume and procedure quality for those suffering from deep vein thrombosis and other clot-related cardiovascular diseases.
